New way to combat Lyme disease performs well in mid-stage trial

26 February 2024
tarsus-large-1

California’s Tarsus Pharmaceuticals (Nasdaq: TARS) has announced positive top-line results from the Phase IIa CARPO trial.

The Irvine-based company is running the trial to test the efficacy of TP-05, also known as lotilaner, in the prevention of Lyme disease.

The most common vector-borne disease in the USA, Lyme disease is transmitted to humans following the bite of ticks which carry it.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical